Lenz Therapeutics Stock Current Valuation
| LENZ Stock | 37.30 1.05 2.90% |
Valuation analysis of LENZ Therapeutics helps investors to measure LENZ Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, LENZ Therapeutics' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.73 in 2024, despite the fact that Enterprise Value is likely to grow to (80.3 M). Fundamental drivers impacting LENZ Therapeutics' valuation include:
Price Book 3.1126 | Enterprise Value 406.1 M | Enterprise Value Ebitda (7.99) |
Overvalued
Today
Please note that LENZ Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of LENZ Therapeutics is based on 3 months time horizon. Increasing LENZ Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since LENZ Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of LENZ Stock. However, LENZ Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 37.3 | Real 33.6 | Target 34.0 | Hype 36.74 |
The intrinsic value of LENZ Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence LENZ Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of LENZ Therapeutics helps investors to forecast how LENZ stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of LENZ Therapeutics more accurately as focusing exclusively on LENZ Therapeutics' fundamentals will not take into account other important factors: LENZ Therapeutics Company Current Valuation Analysis
LENZ Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current LENZ Therapeutics Current Valuation | 406.07 M |
Most of LENZ Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, LENZ Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
LENZ Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for LENZ Therapeutics is extremely important. It helps to project a fair market value of LENZ Stock properly, considering its historical fundamentals such as Current Valuation. Since LENZ Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of LENZ Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of LENZ Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, LENZ Therapeutics has a Current Valuation of 406.07 M. This is 97.17% lower than that of the Biotechnology sector and 91.26% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.56% higher than that of the company.
LENZ Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LENZ Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LENZ Therapeutics could also be used in its relative valuation, which is a method of valuing LENZ Therapeutics by comparing valuation metrics of similar companies.LENZ Therapeutics is currently under evaluation in current valuation category among its peers.
LENZ Fundamentals
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.77 | ||||
| Current Valuation | 406.07 M | ||||
| Shares Outstanding | 27.47 M | ||||
| Shares Owned By Insiders | 5.40 % | ||||
| Shares Owned By Institutions | 86.06 % | ||||
| Number Of Shares Shorted | 2.18 M | ||||
| Price To Book | 3.11 X | ||||
| EBITDA | (122.24 M) | ||||
| Net Income | (124.65 M) | ||||
| Total Debt | 362 K | ||||
| Book Value Per Share | 7.46 X | ||||
| Cash Flow From Operations | (90.01 M) | ||||
| Short Ratio | 17.72 X | ||||
| Earnings Per Share | (2.74) X | ||||
| Target Price | 33.8 | ||||
| Market Capitalization | 600.49 M | ||||
| Total Asset | 188.46 M | ||||
| Retained Earnings | (367.05 M) | ||||
| Annual Yield | 0.89 % | ||||
| Net Asset | 188.46 M |
About LENZ Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LENZ Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LENZ Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LENZ Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.